|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
06955 BOAN BIOTECH
Nominal 
10.390 -0.280 (-2.624%) | 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 726,316 | 17.502% | 618,129 | 515,960 | 158,704 | 0 |
| Cost of Sales | (183,663) | -12.191% | (209,161) | (161,730) | (52,190) | 0 |
| Gross Profit | 542,653 | 32.688% | 408,968 | 354,230 | 106,514 | 0 |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | 73,189 | -- | (119,377) | (331,749) | (225,417) | (240,538) | |
| Taxation | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 0 | -- | 0 | 0 | 0 | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 73,189 | -- | (119,377) | (331,749) | (225,417) | (240,538) | |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 32,246 | 149.428% | 12,928 | 7,839 | 2,498 | 10,624 |
| Depreciation & Amortisation | 72,905 | -11.914% | 82,766 | 72,835 | 50,009 | 15,882 |
| Directors' Emoluments | 17,323 | -12.862% | 19,880 | 17,897 | 19,321 | 2,080 |
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | 14.000 | -- | -23.000 | -67.000 | -47.000 | -- |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | -- | -- |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | (0.220) | -- | (0.036) | (0.405) | (0.515) | -- |
| NBV per share ($) | 3.068 | -- | 2.592 | 2.785 | -- | -- |
| Remarks: | Real time quote last updated: 28/10/2025 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 20,514 |
| %Change | -66.737% |
| EPS / (LPS) | RMB 0.040 |
| NBV Per Share (¥) | RMB 3.540 |